XXII 22nd Century Group Inc

  1. Stocks
  2. Healthcare
  3. NYSEAMERICAN: XXII

Price (delayed)

$0.7739

Market cap

$6.42M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$91.1

Enterprise value

$21.49M

22nd Century is a plant biotechnology company focused on technology which allows it to decrease the level of nicotine in tobacco plants and modify the levels of cannabinoids in hemp/cannabis ...

Highlights
The debt has contracted by 26% YoY
The net income has dropped by 86% year-on-year but it rose by 9% since the previous quarter
22nd Century Group's EPS has increased by 22% from the previous quarter but it has decreased by 10% YoY
The company's equity has shrunk by 114% YoY and by 38% QoQ
The company's gross margin has shrunk by 92% QoQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.xxiicentury.com
Peers: PM MO VGR

Key stats

What are the main financial stats of XXII
Market
Shares outstanding
8.29M
Market cap
$6.42M
Enterprise value
$21.49M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.15
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.29
Earnings
Revenue
$16.71M
EBIT
-$118.32M
EBITDA
-$114.31M
Free cash flow
-$42.39M
Per share
EPS
-$91.1
Free cash flow per share
-$13.39
Book value per share
-$3.34
Revenue per share
$5.28
TBVPS
$5.94
Balance sheet
Total assets
$24.62M
Total liabilities
$36.24M
Debt
$16.59M
Equity
-$11.62M
Working capital
-$11.55M
Liquidity
Debt to equity
-1.43
Current ratio
0.54
Quick ratio
0.21
Net debt/EBITDA
-0.13
Margins
EBITDA margin
-684.1%
Gross margin
-51.8%
Net margin
-767.9%
Operating margin
-188.7%
Efficiency
Return on assets
-235.3%
Return on equity
-855.5%
Return on invested capital
-417.2%
Return on capital employed
N/A
Return on sales
-708.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

XXII stock price

How has the 22nd Century Group stock price performed over time
Intraday
7.49%
1 week
-7.87%
1 month
10.56%
1 year
-74.79%
YTD
315.63%
QTD
3.19%

Financial performance

How have 22nd Century Group's revenue and profit performed over time
Revenue
$16.71M
Gross profit
-$8.65M
Operating income
-$31.54M
Net income
-$128.33M
Gross margin
-51.8%
Net margin
-767.9%
The operating margin has plunged by 112% YoY and by 35% from the previous quarter
The company's gross margin has shrunk by 92% QoQ
The net income has dropped by 86% year-on-year but it rose by 9% since the previous quarter
The net margin has plunged by 76% from the previous quarter

Growth

What is 22nd Century Group's growth rate over time

Valuation

What is 22nd Century Group stock price valuation
P/E
N/A
P/B
N/A
P/S
0.15
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.29
22nd Century Group's EPS has increased by 22% from the previous quarter but it has decreased by 10% YoY
The company's equity has shrunk by 114% YoY and by 38% QoQ
The price to sales (P/S) is 98% lower than the 5-year quarterly average of 7.7 and 80% lower than the last 4 quarters average of 0.7
The revenue has shrunk by 59% YoY and by 48% QoQ

Efficiency

How efficient is 22nd Century Group business performance
22nd Century Group's ROE has plunged by 126% from the previous quarter
22nd Century Group's ROS has plunged by 74% from the previous quarter
The company's return on assets fell by 33% QoQ
The ROIC has contracted by 31% from the previous quarter

Dividends

What is XXII's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for XXII.

Financial health

How did 22nd Century Group financials performed over time
22nd Century Group's total assets is 32% less than its total liabilities
The company's quick ratio has shrunk by 89% YoY and by 9% QoQ
22nd Century Group's total assets has plunged by 80% YoY and by 10% from the previous quarter
The company's equity has shrunk by 114% YoY and by 38% QoQ
XXII's debt to equity is up by 27% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.